ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0021124

female infertility

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. female infertility. Diseases, record MONDO_0021124. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021124

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
female infertility
Open Targets
Open Targets ID
MONDO_0021124
Open Targets
Other names
female reproductive system infertility, female reproductive system infertility disorder, infertility disorder of female reproductive system
Open Targets
MeSH
D007247
MeSH
Highest stage of its drugs
Approval, for 9 of its 15 drugs, from EMA Human Drugs and TTD
Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
LUTROPIN ALFACHEMBL1201419ProteinApprovalEMA Human Drugs and TTD411Drugs and targets
CLOMIPHENE CITRATECHEMBL3185958Small moleculeApprovalTTD211Drugs and targets
FOLLITROPIN ALFACHEMBL1201692ProteinApprovalEMA Human Drugs300Drugs and targets
CHORIOGONADOTROPIN ALFACHEMBL1201464ProteinApprovalEMA Human Drugs and TTD200Drugs and targets
FOLLITROPIN BETACHEMBL5315126ProteinApprovalTTD200Drugs and targets
GANIRELIXCHEMBL1251ProteinApprovalEMA Human Drugs200Drugs and targets
MENOTROPINSCHEMBL2108427ProteinApprovalTTD200Drugs and targets
CLOMIPHENECHEMBL2355051Small moleculeApprovalTTD100Drugs and targets
UROFOLLITROPINCHEMBL1201520ApprovalTTD100Drugs and targets
DYDROGESTERONECHEMBL1200853Small moleculePhase 3ClinicalTrials.gov111Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
FSHRFollicle-stimulating hormone receptor5Follicle stimulating hormone receptor agonistApprovalhttps://conductscience.org/library/genes/2492Drugs and targets
LHCGRLutropin-choriogonadotropic hormone receptor3Luteinizing hormone/Choriogonadotropin receptor agonistApprovalhttps://conductscience.org/library/genes/3973Drugs and targets
ESR1Estrogen receptor2Estrogen receptor alpha modulatorApprovalhttps://conductscience.org/library/genes/2099Drugs and targets
GNRHRGonadotropin-releasing hormone receptor2Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonistApprovalhttps://conductscience.org/library/genes/2798Drugs and targets
PGRProgesterone receptor2Progesterone receptor agonistPhase 3https://conductscience.org/library/genes/5241Drugs and targets
COXFA4Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/4697Drugs and targets
COXFA4L2Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/56901Drugs and targets
GPD2Glycerol-3-phosphate dehydrogenase, mitochondrial1Mitochondrial glycerol-3-phosphate dehydrogenase inhibitorPhase 2https://conductscience.org/library/genes/2820Drugs and targets
MT-ND1Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/4535Drugs and targets
MT-ND2Mitochondrial complex I (NADH dehydrogenase)1Mitochondrial complex I (NADH dehydrogenase) inhibitorPhase 2https://conductscience.org/library/genes/4536Drugs and targets

1 to 10 of 57

See all 57 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01850030
A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization
Phase 31,0702018-01-02Female InfertilityDYDROGESTERONE, PROGESTERONEIts record names the diseaseClinicalTrials.gov
NCT01121991
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Phase 3552011-03-18Infertility, Ovarian StimulationLUTROPIN ALFAIts record names the diseaseClinicalTrials.gov
NCT02024984Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled TrialPhase 190PCOSCLOMIPHENE CITRATEOpen Targets' reading of its recordClinicalTrials.gov
NCT03989778Vitamin D and Polycystic Ovarian Syndrome (PCOS)Early phase 184Infertility, Female, Infertility, Vitamin D DeficiencyERGOCALCIFEROL, METFORMINIts record names the diseaseClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrial
Dydrogesterone 30 mg vs Micronized Progesterone 600 mg: serious adverse events56 of 51868 of 5111,029NCT01850030

Source Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing it
28333318DERIVED1

Source PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021124

GET https://conductscience.org/api/diseases/v1/MONDO_0021124/targets?page=2

API referenceFor AI assistants